StockNews.AI
TELO
StockNews.AI
153 days

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

1. Telomir-1 reduces tumor size by 50% in aggressive prostate cancer models. 2. It also protects against chemotherapy toxicity, enhancing treatment effectiveness.

2m saved
Insight
Article

FAQ

Why Very Bullish?

The significant reduction in tumor size combined with chemo protection could attract investors. Historically, breakthrough findings in oncology often lead to sharp stock price increases.

How important is it?

The findings highlight a potential competitive advantage, making TELO attractive to investors and researchers.

Why Long Term?

Successful preclinical results can lead to clinical trials and market entry, positively impacting long-term projections.

Related Companies

PACLMRKNVS
Telomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced groundbreaking preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive human prostate cancer cells. It was found that Telomir-1 actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel-a widely used chemotherapy drug known for its effectiveness in treating various cancers but often associated with severe toxicity and side effects.

Related News